- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01393223
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Michigan
-
Royal Oak, Michigan, Yhdysvallat
- William Beaumont Hospitals
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
A patient is deemed suitable for inclusion in the study if the patient meets the following criteria:
- Male or female at least 18 years of age
IC/BPS diagnosed by a health care provider based the following criteria:
Complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night time frequency, in the absence of proven urinary infection or other obvious pathology Have had IC/BPS symptoms for at least six months Score of ≥ 12 on the ICSI/PI at baseline Urinary frequency > 10 times a day by self-report and confirmed on baseline three-day voiding diary Have IC/BPS that in the judgment of the investigator has been stable in the previous 30 days IC/BPS-related pain defined as a score of > 3 cm and < 9 cm on the pain VAS where 0 is no pain and 10 is maximum pain
Have had inadequate clinical responses with conservative treatments, which may include one or more of the following: 1) timed voiding and behavioral modification therapy, 2) dietary restrictions, 3) stress reduction and/or 5) oral therapy with any of the following medications:
Antidepressants Antihistamines Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Analgesics Pentosan polysulfate
- Women of childbearing potential: have a negative urine pregnancy test at screening, and must agree to use an acceptable from of contraception (oral contraceptives, intrauterine or double barrier methods), as agreed to by the investigator, during the study period
- Provide signed informed consent
- Subject agrees to be available for the follow-up evaluations as required by the protocol
Exclusion Criteria:
Patients are excluded from enrollment in the study if any of the following are true:
- Currently pregnant or breastfeeding, or plan to become pregnant during the course of the study
- Have received investigational products or devices within 30 days prior to screening visit
- Have received intravesical therapy or bladder hydrodistention within 30 days prior to screening visit. Intravesical instillations may include liquid or drug delivery devices, pentosan polysulfate sodium, lidocaine, steroid, heparin, chondroitin and any combination or additional formulation.
- Have participated in IC/BPS research trial within 90 days prior to screening visit or has not returned to baseline if participated in IC/BPS research trial greater than 90 days prior to screening visit
Have received any of the following medication within 30 days of screening visit, unless such medications have been administered at a stable dose during this month and are expected to remain at a stable dose throughout the study:
Antidepressants Antihistamines (use of antihistamines as needed for allergies is allowed) Anticonvulsants Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Pentosan polysulfate sodium Oral chondroitin
- Have indicated use of > 70 mg of morphine equivalents of opioids per week to control their IC/BPS pain within 30 days prior to screening, or are expected to require this level of IC/BPS pain control during the study period
- Previous augmentation cystoplasty, cystectomy, neurectomy (i.e., hypogastric nerve plexus ablation). Bladder botulinum toxin injections within nine months prior to screening.
- Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting within the past 90 days
- Percutaneous Tibial Nerve Stimulation (PTNS) treatment within the past 90 days
- Evidence of renal impairment (creatinine > two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
- Post-void residual (PVR) urine volume of > 150 mL at screening
- Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
- Previously received intravesical liposomes
- Urinary tract or prostatic infection in the past 90 days before study entry
- Active genital herpes or vaginitis
- Urethral diverticulum
- Pelvic malignancy within the past five years
- History of cyclophosphamide or chemical cystitis, or tuberculosis or pelvic radiation
- History of bladder or prostate tumors (benign or malignant)
- Uncontrolled diabetes
- Has any condition that would preclude treatment due to contraindications and/or warnings in the product labeling
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Active Comparator: LP-08 80mg
4 weekly intravesical administration of LP-08 80mg
|
Intravesical instillation of 80mg LP08
|
Active Comparator: LP-08 20mg
4 weekly intravesical administration of LP-08 20mg
|
Intravesical instillation of 20mg LP08
|
Placebo Comparator: Normal Saline
Four weekly normal saline intravesical administration
|
Intravesical instillation of normal saline
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Safety of Intravesical LP08: number/severity of adverse events
Aikaikkuna: Up to 31 weeks following treatment
|
The number/severity of adverse events throughout the study
|
Up to 31 weeks following treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Efficacy Voids Per Day (VPD)
Aikaikkuna: 2, 4, 8, 16, 24 weeks following treatment
|
The change in voids per day (urinary frequency) as measured on a 3 day voiding diary
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Global Response Assessment (GRA)
Aikaikkuna: 4, 8, 16, 24 weeks following treatment
|
Reporting a "moderate" or "marked" improvement on the GRA
|
4, 8, 16, 24 weeks following treatment
|
Efficacy Symptom
Aikaikkuna: 2, 4, 8, 16, 24 weeks following treatment
|
The change in the symptoms and problems of interstitial cystitis from the baseline as measured by the O'Leary-Sant Interstitial Cystitis Symptom Index
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Visual Analog Scale (VAS)
Aikaikkuna: 2, 4, 8, 16, 24 weeks following treatment
|
The change in pain as recorded on the VAS
|
2, 4, 8, 16, 24 weeks following treatment
|
Efficacy Diary
Aikaikkuna: 2, 4, 8, 16, 24 weeks following treatment
|
The change from baseline in average voided volume, urgency and nocturia episodes per day as measured on a 3 day voiding diary
|
2, 4, 8, 16, 24 weeks following treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- PhaseII LP-08 IC/BPS
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Interstitiaalinen kystiitti
-
La Tour HospitalRive Droite SATuntematonVerihiutalerikas plasma (PRP) | Supraspinatis Interstitial Osittainen paksuus kyyneleetSveitsi
Kliiniset tutkimukset LP-08 80mg
-
3D Medicines (Beijing) Co., Ltd.PeruutettuKiinteä kasvain, aikuinenKiina
-
Guangzhou Magpie Pharmaceuticals Co., Ltd.Ei vielä rekrytointiaKeuhkovaltimon hypertensio
-
Nanjing Zenshine PharmaceuticalsEi vielä rekrytointiaInfluenssa, ihminen
-
Cartesian TherapeuticsRekrytointi
-
Sun Pharma Advanced Research Company LimitedValmisRintasyöpä ja munasarjasyöpä
-
Breath of Life International Pharma LtdPeruutettu
-
AstraZenecaValmisTieteellinen terminologia Krooninen obstruktiivinen keuhkosairaus (COPD) | Maallikoiden terminologia Krooninen keuhkoputkentulehdus ja emfyseemaBulgaria, Saksa, Unkari, Ukraina
-
Centre Hospitalier Universitaire de NiceValmisHematologiset pahanlaatuiset kasvaimetRanska
-
Nihon Pharmaceutical Co., LtdValmisPotilaat, joille tehdään kolonoskopiaJapani
-
Haisco Pharmaceutical Group Co., Ltd.RekrytointiAlkoholiton steatohepatiitti (NASH)Kiina